3.73
0.02 (0.43%)
| Penutupan Terdahulu | 3.71 |
| Jumlah Dagangan | 951,892 |
| Harga / Pendapatan (P/E Ke hadapan) | 40.65 |
| Harga / Jualan (P/S) | 2.07 |
| Harga / Buku (P/B) | 6.60 |
| Julat 52 Minggu |
| Margin Keuntungan | -14.86% |
| Margin Operasi (TTM) | -49.04% |
| EPS Cair (TTM) | -0.230 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 61.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 124.68% |
| Nisbah Semasa (MRQ) | 4.12 |
| Aliran Tunai Operasi (OCF TTM) | -47.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -17.22 M |
| Pulangan Atas Aset (ROA TTM) | -6.58% |
| Pulangan Atas Ekuiti (ROE TTM) | -36.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Ardelyx, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 5.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.50 |
|
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.51% |
| % Dimiliki oleh Institusi | 72.46% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |